NOVO-NORDISK A/S-SPONS ADR (NVO)

US6701002056 - ADR

142.225  -0.27 (-0.19%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (6/14/2024, 9:13:06 AM)

142.225

-0.27 (-0.19%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month46.75%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap633.51B
Shares
PE49.21
Fwd PE33.84
Dividend Yield0.97%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NVO Daily chart

Company Profile

Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880

P: 4544448888

CEO: Lars Fruergaard Jorgensen

Employees: 61412

Website: https://www.novonordisk.com/

NVO News

News Image3 hours ago - InvestorPlace7 A-Rated Biotech Stocks Worth Betting on in June

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

News Image4 hours ago - InvestorPlace3 Stocks to Sell as Ozempic Surges in Popularity

GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity.

News Image4 hours ago - The Motley FoolGot $200? 2 Healthcare Stocks to Buy and Hold Forever.

They aren't the flashiest stocks, but they get the job done.

News Image5 hours ago - The Motley FoolWegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

Novo Nordisk's competition in the obesity drug market is heating up.

News Image21 hours ago - The Motley FoolWeight Loss Drugs: Are They Really Magic?

Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."

News Imagea day ago - InvestorPlace3 Stocks to Buy as Ozempic Surges in Popularity

Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.

NVO Twits

Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example